Selected research
Industry Research
Restless Legs Syndrome Industry Research Report 2026
Market perspective
The global Restless Legs Syndrome market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Restless Legs Syndrome market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Restless Legs Syndrome market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Restless Legs Syndrome market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Restless Legs Syndrome include UCB SA, Omeros Corporation, Manhattan Pharmaceuticals, Ligand Pharmaceuticals Incorporated, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., GlaxoSmithKline plc., Boehringer Ingelheim GmbH and axxonis Pharma AG, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Restless Legs Syndrome market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Restless Legs Syndrome.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Restless Legs Syndrome Market by Company
UCB SA
Omeros Corporation
Manhattan Pharmaceuticals
Ligand Pharmaceuticals Incorporated
Kyowa Hakko Kirin Co.
Jazz Pharmaceuticals, Inc.
GlaxoSmithKline plc.
Boehringer Ingelheim GmbH
axxonis Pharma AG
Astellas
Arbor Pharmaceuticals
Restless Legs Syndrome Segment by Type
Pharmacological Therapy
Non-Pharmacological Therapy
Restless Legs Syndrome Segment by Application
Above 50 Years Old
Below 35 Years Old
From 35 to 50 Years Old
Restless Legs Syndrome Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Restless Legs Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Restless Legs Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Restless Legs Syndrome.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Restless Legs Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pharmacological Therapy
- Non-Pharmacological Therapy
Applications
- Above 50 Years Old
- Below 35 Years Old
- From 35 to 50 Years Old
Companies covered
- UCB SA
- Omeros Corporation
- Manhattan Pharmaceuticals
- Ligand Pharmaceuticals Incorporated
- Kyowa Hakko Kirin Co.
- Jazz Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Boehringer Ingelheim GmbH
- axxonis Pharma AG
- Astellas
- Arbor Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Restless Legs Syndrome by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Pharmacological Therapy
- 2.2.3 Non-Pharmacological Therapy
- 2.3 Restless Legs Syndrome by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Above 50 Years Old
- 2.3.3 Below 35 Years Old
- 2.3.4 From 35 to 50 Years Old
- 2.4 Assumptions and Limitations
3 Restless Legs Syndrome Breakdown Data by Type
- 3.1 Global Restless Legs Syndrome Historic Market Size by Type (2021-2026)
- 3.2 Global Restless Legs Syndrome Forecasted Market Size by Type (2027-2032)
4 Restless Legs Syndrome Breakdown Data by Application
- 4.1 Global Restless Legs Syndrome Historic Market Size by Application (2021-2026)
- 4.2 Global Restless Legs Syndrome Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Restless Legs Syndrome Market Perspective (2021-2032)
- 5.2 Global Restless Legs Syndrome Growth Trends by Region
- 5.2.1 Global Restless Legs Syndrome Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Restless Legs Syndrome Historic Market Size by Region (2021-2026)
- 5.2.3 Restless Legs Syndrome Forecasted Market Size by Region (2027-2032)
- 5.3 Restless Legs Syndrome Market Dynamics
- 5.3.1 Restless Legs Syndrome Industry Trends
- 5.3.2 Restless Legs Syndrome Market Drivers
- 5.3.3 Restless Legs Syndrome Market Challenges
- 5.3.4 Restless Legs Syndrome Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Restless Legs Syndrome Players by Revenue
- 6.1.1 Global Top Restless Legs Syndrome Players by Revenue (2021-2026)
- 6.1.2 Global Restless Legs Syndrome Revenue Market Share by Players (2021-2026)
- 6.2 Global Restless Legs Syndrome Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Restless Legs Syndrome Head Office and Area Served
- 6.4 Global Restless Legs Syndrome Players, Product Type & Application
- 6.5 Global Restless Legs Syndrome Manufacturers Established Date
- 6.6 Global Restless Legs Syndrome Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Restless Legs Syndrome Market Size (2021-2032)
- 7.2 North America Restless Legs Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Restless Legs Syndrome Market Size by Country (2021-2026)
- 7.4 North America Restless Legs Syndrome Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Restless Legs Syndrome Market Size (2021-2032)
- 8.2 Europe Restless Legs Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Restless Legs Syndrome Market Size by Country (2021-2026)
- 8.4 Europe Restless Legs Syndrome Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Restless Legs Syndrome Market Size (2021-2032)
- 9.2 Asia-Pacific Restless Legs Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Restless Legs Syndrome Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Restless Legs Syndrome Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Restless Legs Syndrome Market Size (2021-2032)
- 10.2 South America Restless Legs Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Restless Legs Syndrome Market Size by Country (2021-2026)
- 10.4 South America Restless Legs Syndrome Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Restless Legs Syndrome Market Size (2021-2032)
- 11.2 Middle East & Africa Restless Legs Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Restless Legs Syndrome Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Restless Legs Syndrome Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 UCB SA
- 12.1.1 UCB SA Company Information
- 12.1.2 UCB SA Business Overview
- 12.1.3 UCB SA Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.1.4 UCB SA Restless Legs Syndrome Product Portfolio
- 12.1.5 UCB SA Recent Developments
- 12.2 Omeros Corporation
- 12.2.1 Omeros Corporation Company Information
- 12.2.2 Omeros Corporation Business Overview
- 12.2.3 Omeros Corporation Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.2.4 Omeros Corporation Restless Legs Syndrome Product Portfolio
- 12.2.5 Omeros Corporation Recent Developments
- 12.3 Manhattan Pharmaceuticals
- 12.3.1 Manhattan Pharmaceuticals Company Information
- 12.3.2 Manhattan Pharmaceuticals Business Overview
- 12.3.3 Manhattan Pharmaceuticals Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.3.4 Manhattan Pharmaceuticals Restless Legs Syndrome Product Portfolio
- 12.3.5 Manhattan Pharmaceuticals Recent Developments
- 12.4 Ligand Pharmaceuticals Incorporated
- 12.4.1 Ligand Pharmaceuticals Incorporated Company Information
- 12.4.2 Ligand Pharmaceuticals Incorporated Business Overview
- 12.4.3 Ligand Pharmaceuticals Incorporated Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.4.4 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Portfolio
- 12.4.5 Ligand Pharmaceuticals Incorporated Recent Developments
- 12.5 Kyowa Hakko Kirin Co.
- 12.5.1 Kyowa Hakko Kirin Co. Company Information
- 12.5.2 Kyowa Hakko Kirin Co. Business Overview
- 12.5.3 Kyowa Hakko Kirin Co. Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.5.4 Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Portfolio
- 12.5.5 Kyowa Hakko Kirin Co. Recent Developments
- 12.6 Jazz Pharmaceuticals, Inc.
- 12.6.1 Jazz Pharmaceuticals, Inc. Company Information
- 12.6.2 Jazz Pharmaceuticals, Inc. Business Overview
- 12.6.3 Jazz Pharmaceuticals, Inc. Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.6.4 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Portfolio
- 12.6.5 Jazz Pharmaceuticals, Inc. Recent Developments
- 12.7 GlaxoSmithKline plc.
- 12.7.1 GlaxoSmithKline plc. Company Information
- 12.7.2 GlaxoSmithKline plc. Business Overview
- 12.7.3 GlaxoSmithKline plc. Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.7.4 GlaxoSmithKline plc. Restless Legs Syndrome Product Portfolio
- 12.7.5 GlaxoSmithKline plc. Recent Developments
- 12.8 Boehringer Ingelheim GmbH
- 12.8.1 Boehringer Ingelheim GmbH Company Information
- 12.8.2 Boehringer Ingelheim GmbH Business Overview
- 12.8.3 Boehringer Ingelheim GmbH Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.8.4 Boehringer Ingelheim GmbH Restless Legs Syndrome Product Portfolio
- 12.8.5 Boehringer Ingelheim GmbH Recent Developments
- 12.9 axxonis Pharma AG
- 12.9.1 axxonis Pharma AG Company Information
- 12.9.2 axxonis Pharma AG Business Overview
- 12.9.3 axxonis Pharma AG Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.9.4 axxonis Pharma AG Restless Legs Syndrome Product Portfolio
- 12.9.5 axxonis Pharma AG Recent Developments
- 12.10 Astellas
- 12.10.1 Astellas Company Information
- 12.10.2 Astellas Business Overview
- 12.10.3 Astellas Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.10.4 Astellas Restless Legs Syndrome Product Portfolio
- 12.10.5 Astellas Recent Developments
- 12.11 Arbor Pharmaceuticals
- 12.11.1 Arbor Pharmaceuticals Company Information
- 12.11.2 Arbor Pharmaceuticals Business Overview
- 12.11.3 Arbor Pharmaceuticals Revenue in Restless Legs Syndrome Business (2021-2026)
- 12.11.4 Arbor Pharmaceuticals Restless Legs Syndrome Product Portfolio
- 12.11.5 Arbor Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst